Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D
July 19, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for...
Jnana Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...
Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU
May 31, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
JNT-517 demonstrated proof of mechanism and was safe and well tolerated in healthy volunteers Results support advancement to Phase 1b study in individuals with PKU; study now open for enrollment ...
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche
May 24, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
Achievement of research milestone for immune program triggers milestone payment BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its...